NEW YORK (GenomeWeb News) – Illumina's second-quarter revenues retreated 2 percent year over year, but beat the consensus Wall Street estimate, the company reported after the close of the market on Tuesday.

For the three months ended July 1, the San Diego firm had revenues of $280.6 million, compared to $287.5 million a year ago, and above analyst estimates of $278.7 million. Product revenues slid to $258.8 million from $269.9 million a year ago, while service and other revenues rose to $21.8 million from $17.6 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.